Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and ...

Quarterly Net Profit at Rs. 118.80 crore in December 2024 up 59.81% from Rs. 74.34 crore in December 2023. EBITDA stands at Rs. 244.04 crore in December 2024 up 53.83% from Rs. 158.64 crore in ...

Shares of Piramal Pharma shot up 15% to its new all-time high of Rs 257.95 on the NSE after the company’s second-quarter profit jumped 4 times to Rs 23 crore against Rs 5 crore in the same ...

Operating revenues of ₹2,204.2 crore this quarter rise 12.5% compared with ₹1,958.6 crore in the same period last year ...

The pharmaceutical company's consolidated net profit tumbled 63.6% to Rs 3.68 crore despite of 12.54% increase in revenue from operations to Rs 2,204.22 crore in Q3 FY25 over Q3 FY24.

The drug maker also reported revenue of Rs 2,242 crore for the second quarter compared to Rs 1,911 crore in the year-ago period. Piramal Pharma Solutions (PPS), the global contract manufacturing ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Piramal Pharma Ltd, which has a strong presence in the inhaled anaesthetic generics segment in the US and emerging markets, plans to expand its pipeline of injectables to drive growth, chairperson ...

The company said the third quarter results were not comparable ... 2022 approved the composite scheme of demerger of the pharma business from Piramal Enterprises Ltd (PEL) into Piramal Pharma ...

Piramal Pharma Limited said, "FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance ...

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 * global development and manufacturing facilities and a global ...